- Sanofi's license extension with Nurix includes a $15 million payment, raising total collaboration funds to $127 million.
- Nurix retains the potential to earn up to $465 million in future milestones and royalties under the agreement.
- NX-3911 shows promising preclinical efficacy in atopic dermatitis and asthma by degrading the STAT6 protein.
Sanofi has cemented its collaboration with Nurix Therapeutics (NRIX, Financial) by exercising its option to exclusively license Nurix's STAT6 program, which includes NX-3911, an oral STAT6 degrader. This decision triggers an immediate $15 million payment to Nurix, pushing total receipts from their collaboration to $127 million since its inception in 2019.
Nurix remains eligible for up to $465 million in additional development, regulatory, and commercial milestones and potential royalties. The agreement allows Nurix to retain U.S. co-development and co-promotion rights for certain products, offering potential 50% profit sharing from U.S. sales if they choose to exercise these rights.
NX-3911, developed using Nurix's DEL-AI platform, offers a targeted approach by degrading STAT6, a transcription factor involved in type 2 inflammation seen in atopic dermatitis and asthma. Preclinical studies indicate that NX-3911 achieves full degradation of STAT6 with efficacy comparable to complete STAT6 gene knockout in animal models.
This marks the second license extension Sanofi has enacted within 90 days for Nurix's autoimmune programs, further affirming the potential of Nurix's innovative drug discovery platform. The ongoing collaboration between the two companies aims to explore groundbreaking treatments using targeted protein degradation, a field where Nurix has established significant expertise.
